Movatterモバイル変換

[0]ホーム
URL:

US20030148370A1 - Secreted and transmembrane polypeptides and nucleic acids encoding the same - Google Patents

Secreted and transmembrane polypeptides and nucleic acids encoding the sameDownload PDF

Info

Publication number
US20030148370A1
US20030148370A1US09/904,838US90483801AUS2003148370A1US 20030148370 A1US20030148370 A1US 20030148370A1US 90483801 AUS90483801 AUS 90483801AUS 2003148370 A1US2003148370 A1US 2003148370A1
Authority
US
United States
Prior art keywords
seq
atcc
polypeptide
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/904,838
Inventor
Avi Ashkenazi
David Botstein
Luc Desnoyers
Dan Eaton
Napoleone Ferrara
Ellen Filvaroff
Sherman Fong
Wei-Qiang Gao
Hanspeter Gerber
Mary Gerritsen
Audrey Goddard
Paul Godowski
J. Grimaldi
Austin Gurney
Kenneth Hillan
Ivar Kljavin
Jennie Mather
James Pan
Nicholas Paoni
Margaret Roy
Timothy Stewart
Daniel Tumas
P. Williams
William Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=43706158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20030148370(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US1998/018824external-prioritypatent/WO1999014327A2/en
Priority claimed from PCT/US1998/019177external-prioritypatent/WO1999014234A2/en
Priority claimed from PCT/US1998/019330external-prioritypatent/WO1999014328A2/en
Priority claimed from PCT/US1998/019437external-prioritypatent/WO1999014241A2/en
Priority claimed from PCT/US1998/025108external-prioritypatent/WO1999028462A2/en
Priority claimed from PCT/US1999/020594external-prioritypatent/WO2000015666A2/en
Priority claimed from PCT/US1999/020944external-prioritypatent/WO2000015792A2/en
Priority claimed from PCT/US1999/021547external-prioritypatent/WO2000015797A2/en
Priority claimed from PCT/US1999/021090external-prioritypatent/WO2000015796A2/en
Priority claimed from PCT/US1999/023089external-prioritypatent/WO2000021996A2/en
Priority claimed from PCT/US1999/028214external-prioritypatent/WO2001019987A1/en
Priority claimed from PCT/US1999/028313external-prioritypatent/WO2000032221A2/en
Priority claimed from PCT/US1999/028301external-prioritypatent/WO2000032776A2/en
Priority claimed from PCT/US1999/028564external-prioritypatent/WO2000055319A1/en
Priority claimed from PCT/US1999/028565external-prioritypatent/WO2000037638A2/en
Priority claimed from PCT/US1999/030095external-prioritypatent/WO2000037640A2/en
Priority claimed from PCT/US1999/030999external-prioritypatent/WO2001005836A1/en
Priority claimed from PCT/US1999/030911external-prioritypatent/WO2000075316A1/en
Priority claimed from PCT/US2000/000219external-prioritypatent/WO2000053753A2/en
Priority claimed from PCT/US2000/003565external-prioritypatent/WO2001053486A1/en
Priority claimed from PCT/US2000/004414external-prioritypatent/WO2001004311A1/en
Priority claimed from PCT/US2000/005004external-prioritypatent/WO2000053757A2/en
Priority claimed from PCT/US2000/005841external-prioritypatent/WO2000053758A2/en
Priority claimed from PCT/US2000/007377external-prioritypatent/WO2001019991A1/en
Priority claimed from PCT/US2000/008439external-prioritypatent/WO2000073454A1/en
Priority claimed from PCT/US2000/014042external-prioritypatent/WO2000077037A2/en
Priority claimed from PCT/US2000/015264external-prioritypatent/WO2000073452A2/en
Priority claimed from PCT/US2000/020710external-prioritypatent/WO2001009327A2/en
Priority claimed from PCT/US2000/023328external-prioritypatent/WO2001016318A2/en
Application filed by Genentech IncfiledCriticalGenentech Inc
Priority to US09/904,838priorityCriticalpatent/US20030148370A1/en
Publication of US20030148370A1publicationCriticalpatent/US20030148370A1/en
Abandonedlegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Description

Claims (38)

What is claimed is:
1. Isolated nucleic acid having at least 80% sequence identity to a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:2), FIG. 4 (SEQ ID NO:4), FIG. 6 (SEQ ID NO:12), FIG. 9 (SEQ ID NO:18), FIG. 11 (SEQ ID NO:23), FIG. 13 (SEQ ID NO:28), FIG. 15 (SEQ ID NO:34), FIG. 17 (SEQ ID NO:39), FIG. 19 (SEQ ID NO:49), FIG. 22 (SEQ ID NO:59), FIG. 24 (SEQ ID NO:64), FIG. 26 (SEQ ID NO:69), FIG. 28 (SEQ ID NO:71), FIG. 30 (SEQ ID NO:73), FIG. 32 (SEQ ID NO:84), FIG. 34 (SEQ ID NO:91), FIG. 36 (SEQ ID NO:96), FIG. 38 (SEQ ID NO:104), FIG. 40 (SEQ ID NO:109), FIG. 42 (SEQ ID NO:114), FIG. 44 (SEQ ID NO:119), FIG. 46 (SEQ ID NO:127), FIG. 48 (SEQ ID NO:132), FIG. 50 (SEQ ID NO:137), FIG. 52 (SEQ ID NO:142), FIG. 54 (SEQ ID NO:148), FIG. 56 (SEQ ID NO:153), FIG. 58 (SEQ ID NO:159), FIG. 60 (SEQ ID NO:164), FIG. 62 (SEQ ID NO:170), FIG. 64 (SEQ ID NO:175), FIG. 66 (SEQ ID NO:177), FIG. 68 (SEQ ID NO:185), FIG. 70 (SEQ ID NO:190), FIG. 72 (SEQ ID NO:195), FIG. 74 (SEQ ID NO:201), FIG. 76 (SEQ ID NO:207), FIG. 78 (SEQ ID NO:213), FIG. 80 (SEQ ID NO:221), FIG. 82 (SEQ ID NO:227), FIG. 84 (SEQ ID NO:236), FIG. 86 (SEQ ID NO:245), FIG. 88 (SEQ ID NO:250), FIG. 90 (SEQ ID NO:255), FIG. 92 (SEQ ID NO:257), FIG. 94 (SEQ ID NO:259), FIG. 96 (SEQ ID NO:261), FIG. 98 (SEQ ID NO:263), FIG. 100 (SEQ ID NO:285), FIG. 102 (SEQ ID NO:290), FIG. 104 (SEQ ID NO:292), FIG. 106 (SEQ ID NO:294), FIG. 108 (SEQ ID NO:310), FIG. 110 (SEQ ID NO:315), FIG. 112 (SEQ ID NO:320), FIG. 114 (SEQ ID NO:325), FIG. 116 (SEQ ID NO:332), FIG. 118 (SEQ ID NO:339), FIG. 120 (SEQ ID NO:341), FIG. 122 (SEQ ID NO:377) and FIG. 124 (SEQ ID NO:423).
2. The nucleic acid ofclaim 1, wherein said nucleotide sequence comprises a nucleotide sequence selected from the group consisting of the sequence shown in FIG. 1 (SEQ ID NO:1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:11), FIG. 8 (SEQ ID NO:17), FIG. 10 (SEQ ID NO:22), FIG. 12 (SEQ ID NO:27), FIG. 14 (SEQ ID NO:33), FIG. 16 (SEQ ID NO:38), FIG. 18 (SEQ ID NO:48), FIG. 21 (SEQ ID NO:58), FIG. 23 (SEQ ID NO:63), FIG. 25 (SEQ ID NO:68), FIG. 27 (SEQ ID NO:70), FIG. 29 (SEQ ID NO:72), FIG. 31 (SEQ ID NO:83), FIG. 33 (SEQ ID NO:90), FIG. 35 (SEQ ID NO:95), FIG. 37 (SEQ ID NO:103), FIG. 39 (SEQ ID NO:108), FIG. 41 (SEQ ID NO:113), FIG. 43 (SEQ ID NO:118), FIG. 45 (SEQ ID NO:126), FIG. 47 (SEQ ID NO:131), FIG. 49 (SEQ ID NO:136), FIG. 51 (SEQ ID NO:141), FIG. 53 (SEQ ID NO:147), FIG. 55 (SEQ ID NO:152), FIG. 57 (SEQ ID NO:158), FIG. 59 (SEQ ID NO:163), FIG. 61 (SEQ ID NO:169), FIG. 63 (SEQ ID NO:174), FIG. 65 (SEQ ID NO:176), FIG. 67 (SEQ ID NO:184), FIG. 69 (SEQ ID NO:189), FIG. 71 (SEQ ID NO:194), FIG. 73 (SEQ ID NO:200), FIG. 75 (SEQ ID NO:206), FIG. 77 (SEQ ID NO:212), FIG. 79 (SEQ ID NO:220), FIG. 81 (SEQ ID NO:226), FIG. 83 (SEQ ID NO:235), FIG. 85 (SEQ ID NO:244), FIG. 87 (SEQ ID NO:249), FIG. 89 (SEQ ID NO:254), FIG. 91 (SEQ ID NO:256), FIG. 93 (SEQ ID NO:258), FIG. 95 (SEQ ID NO:260), FIG. 97 (SEQ ID NO:262), FIG. 99 (SEQ ID NO:284), FIG. 101 (SEQ ID NO:289), FIG. 103 (SEQ ID NO:291), FIG. 105 (SEQ ID NO:293), FIG. 107 (SEQ ID NO:309), FIG. 109 (SEQ ID NO:314), FIG. 111 (SEQ ID NO:319), FIG. 113 (SEQ ID NO:324), FIG. 115 (SEQ ID NO:331), FIG. 117 (SEQ ID NO:338), FIG. 119 (SEQ ID NO:340), FIG. 121 (SEQ ID NO:376) and FIG. 123 (SEQ ID NO:422), or the complement thereof.
3. The nucleic acid ofclaim 1, wherein said nucleotide sequence comprises a nucleotide sequence selected from the group consisting of the full-length coding sequence of the sequence shown in FIG. 1 (SEQ ID NO:1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:1), FIG. 8 (SEQ ID NO:17), FIG. 10 (SEQ ID NO:22), FIG. 12 (SEQ ID NO:27), FIG. 14 (SEQ ID NO:33), FIG. 16 (SEQ ID NO:38), FIG. 18 (SEQ ID NO:48), FIG. 21 (SEQ ID NO:58), FIG. 23 (SEQ ID NO:63), FIG. 25 (SEQ ID NO:68), FIG. 27 (SEQ ID NO:70), FIG. 29 (SEQ ID NO:72), FIG. 31 (SEQ ID NO:83), FIG. 33 (SEQ ID NO:90), FIG. 35 (SEQ ID NO:95), FIG. 37 (SEQ ID NO:103), FIG. 39 (SEQ ID NO:108), FIG. 41 (SEQ ID NO:113), FIG. 43 (SEQ ID NO:118), FIG. 45 (SEQ ID NO:126), FIG. 47 (SEQ ID NO:131), FIG. 49 (SEQ ID NO:136), FIG. 51 (SEQ ID NO:141), FIG. 53 (SEQ ID NO:147), FIG. 55 (SEQ ID NO:152), FIG. 57 (SEQ ID NO:158), FIG. 59 (SEQ ID NO:163), FIG. 61 (SEQ ID NO:169), FIG. 63 (SEQ ID NO:174), FIG. 65 (SEQ ID NO:176), FIG. 67 (SEQ ID NO:184), FIG. 69 (SEQ ID NO:189), FIG. 71 (SEQ ID NO:194), FIG. 73 (SEQ ID NO:200), FIG. 75 (SEQ ID NO:206), FIG. 77 (SEQ ID NO:212), FIG. 79 (SEQ ID NO:220), FIG. 81 (SEQ ID NO:226), FIG. 83 (SEQ ID NO:235), FIG. 85 (SEQ ID NO:244), FIG. 87 (SEQ ID NO:249), FIG. 89 (SEQ ID NO:254), FIG. 91 (SEQ ID NO:256), FIG. 93 (SEQ ID NO:258), FIG. 95 (SEQ ID NO:260), FIG. 97 (SEQ ID NO:262), FIG. 99 (SEQ ID NO:284), FIG. 101 (SEQ ID NO:289), FIG. 103 (SEQ ID NO:291), FIG. 105 (SEQ ID NO:293), FIG. 107 (SEQ ID NO:309), FIG. 109 (SEQ ID NO:314), FIG. 111 (SEQ ID NO:319), FIG. 113 (SEQ ID NO:324), FIG. 115 (SEQ ID NO:331), FIG. 117 (SEQ ID NO:338), FIG. 119 (SEQ ID NO:340), FIG. 121 (SEQ ID NO:376) and FIG. 123 (SEQ ID NO:422), or the complement thereof.
4. Isolated nucleic acid which comprises the full-length coding sequence of the DNA deposited under accession number ATCC 209258, ATCC 209256, ATCC 209264, ATCC 209250, ATCC 209375, ATCC 209378, ATCC 209384, ATCC 209396, ATCC 209420, ATCC 209480, ATCC 209265, ATCC 209257, ATCC 209262, ATCC 209253, ATCC 209402, ATCC 209401, ATCC 209397, ATCC 209400, ATCC 209385, ATCC 209367, ATCC 209432, ATCC 209263, ATCC 209251, ATCC 209255, ATCC 209252, ATCC 209373, ATCC 209370, ATCC 209523, ATCC 209372, ATCC 209374, ATCC 209373, ATCC 209382, ATCC 209383, ATCC 209403, ATCC 209398, ATCC 209399, ATCC 209392, ATCC 209387, ATCC 209388, ATCC 209394, ATCC 209421, ATCC 209393, ATCC 209418, ATCC 209485, ATCC 209483, ATCC 209482, ATCC 209491, ATCC 209481, ATCC 209438, ATCC 209927, ATCC 209439, ATCC 209489, ATCC 209433, ATCC 209488, ATCC 209434, ATCC 209395, ATCC 209486, ATCC 209490, ATCC 209484, ATCC 209371 or ATCC 203553.
5. A vector comprising the nucleic acid ofclaim 1.
6. The vector ofclaim 5 operably linked to control sequences recognized by a host cell transformed with the vector.
7. A host cell comprising the vector ofclaim 5.
8. The host cell ofclaim 7 wherein said cell is a CHO cell.
9. The host cell ofclaim 7 wherein said cell is anE. coli.
10. The host cell ofclaim 7 wherein said cell is a yeast cell.
11. A process for producing a PRO polypeptides comprising culturing the host cell ofclaim 7 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.
12. Isolated native sequence PRO polypeptide having at least 80% sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:2), FIG. 4 (SEQ ID NO:4), FIG. 6 (SEQ ID NO:12), FIG. 9 (SEQ ID NO:18), FIG. 11 (SEQ ID NO:23), FIG. 13 (SEQ ID NO:28), FIG. 15 (SEQ ID NO:34), FIG. 17 (SEQ ID NO:39), FIG. 19 (SEQ ID NO:49), FIG. 22 (SEQ ID NO:59), FIG. 24 (SEQ ID NO:64), FIG. 26 (SEQ ID NO:69), FIG. 28 (SEQ ID NO:71), FIG. 30 (SEQ ID NO:73), FIG. 32 (SEQ ID NO:84), FIG. 34 (SEQ ID NO:91), FIG. 36 (SEQ ID NO:96), FIG. 38 (SEQ ID NO:104), FIG. 40 (SEQ ID NO:109), FIG. 42 (SEQ ID NO:114), FIG. 44 (SEQ ID NO:119), FIG. 46 (SEQ ID NO:127), FIG. 48 (SEQ ID NO:132), FIG. 50 (SEQ ID NO:137), FIG. 52 (SEQ ID NO:142), FIG. 54 (SEQ ID NO:148), FIG. 56 (SEQ ID NO:153), FIG. 58 (SEQ ID NO:159), FIG. 60 (SEQ ID NO:164), FIG. 62 (SEQ ID NO:170), FIG. 64 (SEQ ID NO:175), FIG. 66 (SEQ ID NO:177), FIG. 68 (SEQ ID NO:185), FIG. 70 (SEQ ID NO:190), FIG. 72 (SEQ ID NO:195), FIG. 74 (SEQ ID NO:201), FIG. 76 (SEQ ID NO:207), FIG. 78 (SEQ ID NO:213), FIG. 80 (SEQ ID NO:221), FIG. 82 (SEQ ID NO:227), FIG. 84 (SEQ ID NO:236), FIG. 86 (SEQ ID NO:245), FIG. 88 (SEQ ID NO:250), FIG. 90 (SEQ ID NO:255), FIG. 92 (SEQ ID NO:257), FIG. 94 (SEQ ID NO:259), FIG. 96 (SEQ ID NO:261), FIG. 98 (SEQ ID NO:263), FIG. 100 (SEQ ID NO:285), FIG. 102 (SEQ ID NO:290), FIG. 104 (SEQ ID NO:292), FIG. 106 (SEQ ID NO:294), FIG. 108 (SEQ ID NO:310), FIG. 110 (SEQ ID NO:315), FIG. 112 (SEQ ID NO:320), FIG. 114 (SEQ ID NO:325), FIG. 116 (SEQ ID NO:332), FIG. 118 (SEQ ID NO:339), FIG. 120 (SEQ ID NO:341), FIG. 122 (SEQ ID NO:377) and FIG. 124 (SEQ ID NO:423).
13. Isolated PRO polypeptide having at least 80% sequence identity to the amino acid sequence encoded by the nucleotide deposited under accession number ATCC 209258, ATCC 209256, ATCC 209264, ATCC 209250, ATCC 209375, ATCC 209378, ATCC 209384, ATCC 209396, ATCC 209420, ATCC 209480, ATCC 209265, ATCC 209257, ATCC 209262, ATCC 209253, ATCC 209402, ATCC 209401, ATCC 209397, ATCC 209400, ATCC 209385, ATCC 209367, ATCC 209432, ATCC 209263, ATCC 209251, ATCC 209255, ATCC 209252, ATCC 209373, ATCC 209370, ATCC 209523, ATCC 209372, ATCC 209374, ATCC 209373, ATCC 209382, ATCC 209383, ATCC 209403, ATCC 209398, ATCC 209399, ATCC 209392, ATCC 209387, ATCC 209388, ATCC 209394, ATCC 209421, ATCC 209393, ATCC 209418, ATCC 209485, ATCC 209483, ATCC 209482, ATCC 209491, ATCC 209481, ATCC 209438, ATCC 209927, ATCC 209439, ATCC 209489, ATCC 209433, ATCC 209488, ATCC 209434, ATCC 209395, ATCC 209486, ATCC 209490, ATCC 209484, ATCC 209371 or ATCC 203553.
14. A chimeric molecule comprising a polypeptide according toclaim 12 fused to a heterologous amino acid sequence.
15. The chimeric molecule ofclaim 14 wherein said heterologous amino acid sequence is an epitope tag sequence.
16. The chimeric molecule ofclaim 14 wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.
17. An antibody which specifically binds to a PRO polypeptide according toclaim 12.
18. The antibody ofclaim 17 wherein said antibody is a monoclonal antibody.
19. Isolated nucleic acid having at least 80% nucleic acid sequence identity to:
(a) a nucleotide sequence encoding the polypeptide shown in FIG. 2 (SEQ ID NO:2), FIG. 4 (SEQ ID NO:4), FIG. 6 (SEQ ID NO:12), FIG. 9 (SEQ ID NO:18), FIG. 11 (SEQ ID NO:23), FIG. 13 (SEQ ID NO:28), FIG. 15 (SEQ ID NO:34), FIG. 17 (SEQ ID NO:39), FIG. 19 (SEQ ID NO:49), FIG. 22 (SEQ ID NO:59), FIG. 24 (SEQ ID NO:64), FIG. 26 (SEQ ID NO:69), FIG. 28 (SEQ ID NO:71), FIG. 30 (SEQ ID NO:73), FIG. 32 (SEQ ID NO:84), FIG. 34 (SEQ ID NO:91), FIG. 36 (SEQ ID NO:96), FIG. 38 (SEQ ID NO:104), FIG. 40 (SEQ ID NO:109), FIG. 42 (SEQ ID NO:114), FIG. 44 (SEQ ID NO:119), FIG. 46 (SEQ ID NO:127), FIG. 48 (SEQ ID NO:132), FIG. 50 (SEQ ID NO:137), FIG. 52 (SEQ ID NO:142), FIG. 54 (SEQ ID NO:148), FIG. 56 (SEQ ID NO:153), FIG. 58 (SEQ ID NO:159), FIG. 60 (SEQ ID NO:164), FIG. 62 (SEQ ID NO:170), FIG. 64 (SEQ ID NO:175), FIG. 66 (SEQ ID NO:177), FIG. 68 (SEQ ID NO:185), FIG. 70 (SEQ ID NO:190), FIG. 72 (SEQ ID NO:195), FIG. 74 (SEQ ID NO:201), FIG. 76 (SEQ ID NO:207), FIG. 78 (SEQ ID NO:213), FIG. 80 (SEQ ID NO:221), FIG. 82 (SEQ ID NO:227), FIG. 84 (SEQ ID NO:236), FIG. 86 (SEQ ID NO:245), FIG. 88 (SEQ ID NO:250), FIG. 90 (SEQ ID NO:255), FIG. 92 (SEQ ID NO:257), FIG. 94 (SEQ ID NO:259), FIG. 96 (SEQ ID NO:261), FIG. 98 (SEQ ID NO:263), FIG. 100 (SEQ ID NO:285), FIG. 102 (SEQ ID NO:290), FIG. 104 (SEQ ID NO:292), FIG. 106 (SEQ ID NO:294), FIG. 108 (SEQ ID NO:310), FIG. 110 (SEQ ID NO:315), FIG. 112 (SEQ ID NO:320), FIG. 114 (SEQ ID NO:325), FIG. 116 (SEQ ID NO:332), FIG. 118 (SEQ ID NO:339), FIG. 120 (SEQ ID NO:341), FIG. 122 (SEQ ID NO:377) or FIG. 124 (SEQ ID NO:423), lacking its associated signal peptide;
(b) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in FIG. 2 (SEQ ID NO:2), FIG. 4 (SEQ ID NO:4), FIG. 6 (SEQ ID NO:12), FIG. 9 (SEQ ID NO:18), FIG. 11 (SEQ ID NO:23), FIG. 13 (SEQ ID NO:28), FIG. 15 (SEQ ID NO:34), FIG. 17 (SEQ ID NO:39), FIG. 19 (SEQ ID NO:49), FIG. 22 (SEQ ID NO:59), FIG. 24 (SEQ ID NO:64), FIG. 26 (SEQ ID NO:69), FIG. 28 (SEQ ID NO:71), FIG. 30 (SEQ ID NO:73), FIG. 32 (SEQ ID NO:84), FIG. 34 (SEQ ID NO:91), FIG. 36 (SEQ ID NO:96), FIG. 38 (SEQ ID NO:104), FIG. 40 (SEQ ID NO:109), FIG. 42 (SEQ ID NO:114), FIG. 44 (SEQ ID NO:119), FIG. 46 (SEQ ID NO:127), FIG. 48 (SEQ ID NO:132), FIG. 50 (SEQ ID NO:137), FIG. 52 (SEQ ID NO:142), FIG. 54 (SEQ ID NO:148), FIG. 56 (SEQ ID NO:153), FIG. 58 (SEQ ID NO:159), FIG. 60 (SEQ ID NO:164), FIG. 62 (SEQ ID NO:170), FIG. 64 (SEQ ID NO:175), FIG. 66 (SEQ ID NO:177), FIG. 68 (SEQ ID NO:185), FIG. 70 (SEQ ID NO:190), FIG. 72 (SEQ ID NO:195), FIG. 74 (SEQ ID NO:201), FIG. 76 (SEQ ID NO:207), FIG. 78 (SEQ ID NO:213), FIG. 80 (SEQ ID NO:221), FIG. 82 (SEQ ID NO:227), FIG. 84 (SEQ ID NO:236), FIG. 86 (SEQ ID NO:245), FIG. 88 (SEQ ID NO:250), FIG. 90 (SEQ ID NO:255), FIG. 92 (SEQ ID NO:257), FIG. 94 (SEQ ID NO:259), FIG. 96 (SEQ ID NO:261), FIG. 98 (SEQ ID NO:263), FIG. 100 (SEQ ID NO:285), FIG. 102 (SEQ ID NO:290), FIG. 104 (SEQ ID NO:292), FIG. 106 (SEQ ID NO:294), FIG. 108 (SEQ ID NO:310), FIG. 110 (SEQ ID NO:315), FIG. 112 (SEQ ID NO:320), FIG. 114 (SEQ ID NO:325), FIG. 116 (SEQ ID NO:332), FIG. 118 (SEQ ID NO:339), FIG. 120 (SEQ ID NO:341), FIG. 122 (SEQ ID NO:377) or FIG. 124 (SEQ ID NO:423), with its associated signal peptide; or
(c) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in FIG. 2 (SEQ ID NO:2), FIG. 4 (SEQ ID NO:4), FIG. 6 (SEQ ID NO:12), FIG. 9 (SEQ ID NO:18), FIG. 11 (SEQ ID NO:23), FIG. 13 (SEQ ID NO:28), FIG. 15 (SEQ ID NO:34), FIG. 17 (SEQ ID NO:39), FIG. 19 (SEQ ID NO:49), FIG. 22 (SEQ ID NO:59), FIG. 24 (SEQ ID NO:64), FIG. 26 (SEQ ID NO:69), FIG. 28 (SEQ ID NO:71), FIG. 30 (SEQ ID NO:73), FIG. 32 (SEQ ID NO:84), FIG. 34 (SEQ ID NO:91), FIG. 36 (SEQ ID NO:96), FIG. 38 (SEQ ID NO:104), FIG. 40 (SEQ ID NO:109), FIG. 42 (SEQ ID NO:114), FIG. 44 (SEQ ID NO:119), FIG. 46 (SEQ ID NO:127), FIG. 48 (SEQ ID NO:132), FIG. 50 (SEQ ID NO:137), FIG. 52 (SEQ ID NO:142), FIG. 54 (SEQ ID NO:148), FIG. 56 (SEQ ID NO:153), FIG. 58 (SEQ ID NO:159), FIG. 60 (SEQ ID NO:164), FIG. 62 (SEQ ID NO:170), FIG. 64 (SEQ ID NO:175), FIG. 66 (SEQ ID NO:177), FIG. 68 (SEQ ID NO:185), FIG. 70 (SEQ ID NO:190), FIG. 72 (SEQ ID NO:195), FIG. 74 (SEQ ID NO:201), FIG. 76 (SEQ ID NO:207), FIG. 78 (SEQ ID NO:213), FIG. 80 (SEQ ID NO:221), FIG. 82 (SEQ ID NO:227), FIG. 84 (SEQ ID NO:236), FIG. 86 (SEQ ID NO:245), FIG. 88 (SEQ ID NO:250), FIG. 90 (SEQ ID NO:255), FIG. 92 (SEQ ID NO:257), FIG. 94 (SEQ ID NO:259), FIG. 96 (SEQ ID NO:261), FIG. 98 (SEQ ID NO:263), FIG. 100 (SEQ ID NO:285), FIG. 102 (SEQ ID NO:290), FIG. 104 (SEQ ID NO:292), FIG. 106 (SEQ ID NO:294), FIG. 108 (SEQ ID NO:310), FIG. 110 (SEQ ID NO:315), FIG. 112 (SEQ ID NO:320), FIG. 114 (SEQ ID NO:325), FIG. 116 (SEQ ID NO:332), FIG. 118 (SEQ ID NO:339), FIG. 120 (SEQ ID NO:341), FIG. 122 (SEQ ID NO:377) or FIG. 124 (SEQ ID NO:423), lacking its associated signal peptide.
20. An isolated polypeptide having at least 80% amino acid sequence identity to:
(a) the polypeptide shown in FIG. 2 (SEQ ID NO:2), FIG. 4 (SEQ ID NO:4), FIG. 6 (SEQ ID NO:12), FIG. 9 (SEQ ID NO:18), FIG. 11 (SEQ ID NO:23), FIG. 13 (SEQ ID NO:28), FIG. 15 (SEQ ID NO:34), FIG. 17 (SEQ ID NO:39), FIG. 19 (SEQ ID NO:49), FIG. 22 (SEQ ID NO:59), FIG. 24 (SEQ ID NO:64), FIG. 26 (SEQ ID NO:69), FIG. 28 (SEQ ID NO:71), FIG. 30 (SEQ ID NO:73), FIG. 32 (SEQ ID NO:84), FIG. 34 (SEQ ID NO:91), FIG. 36 (SEQ ID NO:96), FIG. 38 (SEQ ID NO:104), FIG. 40 (SEQ ID NO:109), FIG. 42 (SEQ ID NO:114), FIG. 44 (SEQ ID NO:119), FIG. 46 (SEQ ID NO:127), FIG. 48 (SEQ ID NO:132), FIG. 50 (SEQ ID NO:137), FIG. 52 (SEQ ID NO:142), FIG. 54 (SEQ ID NO:148), FIG. 56 (SEQ ID NO:153), FIG. 58 (SEQ ID NO:159), FIG. 60 (SEQ ID NO:164), FIG. 62 (SEQ ID NO:170), FIG. 64 (SEQ ID NO:175), FIG. 66 (SEQ ID NO:177), FIG. 68 (SEQ ID NO:185), FIG. 70 (SEQ ID NO:190), FIG. 72 (SEQ ID NO:195), FIG. 74 (SEQ ID NO:201), FIG. 76 (SEQ ID NO:207), FIG. 78 (SEQ ID NO:213), FIG. 80 (SEQ ID NO:221), FIG. 82 (SEQ ID NO:227), FIG. 84 (SEQ ID NO:236), FIG. 86 (SEQ ID NO:245), FIG. 88 (SEQ ID NO:250), FIG. 90 (SEQ ID NO:255), FIG. 92 (SEQ ID NO:257), FIG. 94 (SEQ ID NO:259), FIG. 96 (SEQ ID NO:261), FIG. 98 (SEQ ID NO:263), FIG. 100 (SEQ ID NO:285), FIG. 102 (SEQ ID NO:290), FIG. 104 (SEQ ID NO:292), FIG. 106 (SEQ ID NO:294), FIG. 108 (SEQ ID NO:310), FIG. 110 (SEQ ID NO:315), FIG. 112 (SEQ ID NO:320), FIG. 114 (SEQ ID NO:325), FIG. 116 (SEQ ID NO:332), FIG. 118 (SEQ ID NO:339), FIG. 120 (SEQ ID NO:341), FIG. 122 (SEQ ID NO:377) or FIG. 124 (SEQ ID NO:423), lacking its associated signal peptide;
(b) an extracellular domain of the polypeptide shown in FIG. 2 (SEQ ID NO:2), FIG. 4 (SEQ ID NO:4), FIG. 6 (SEQ ID NO:12), FIG. 9 (SEQ ID NO:18), FIG. 11 (SEQ ID NO:23), FIG. 13 (SEQ ID NO:28), FIG. 15 (SEQ ID NO:34), FIG. 17 (SEQ ID NO:39), FIG. 19 (SEQ ID NO:49), FIG. 22 (SEQ ID NO:59), FIG. 24 (SEQ ID NO:64), FIG. 26 (SEQ ID NO:69), FIG. 28 (SEQ ID NO:71), FIG. 30 (SEQ ID NO:73), FIG. 32 (SEQ ID NO:84), FIG. 34 (SEQ ID NO:91), FIG. 36 (SEQ ID NO:96), FIG. 38 (SEQ ID NO:104), FIG. 40 (SEQ ID NO:109), FIG. 42 (SEQ ID NO:114), FIG. 44 (SEQ ID NO:119), FIG. 46 (SEQ ID NO:127), FIG. 48 (SEQ ID NO:132), FIG. 50 (SEQ ID NO:137), FIG. 52 (SEQ ID NO:142), FIG. 54 (SEQ ID NO:148), FIG. 56 (SEQ ID NO:153), FIG. 58 (SEQ ID NO:159), FIG. 60 (SEQ ID NO:164), FIG. 62 (SEQ ID NO:170), FIG. 64 (SEQ ID NO:175), FIG. 66 (SEQ ID NO:177), FIG. 68 (SEQ ID NO:185), FIG. 70 (SEQ ID NO:190), FIG. 72 (SEQ ID NO:195), FIG. 74 (SEQ ID NO:201), FIG. 76 (SEQ ID NO:207), FIG. 78 (SEQ ID NO:213), FIG. 80 (SEQ ID NO:221), FIG. 82 (SEQ ID NO:227), FIG. 84 (SEQ ID NO:236), FIG. 86 (SEQ ID NO:245), FIG. 88 (SEQ ID NO:250), FIG. 90 (SEQ ID NO:255), FIG. 92 (SEQ ID NO:257), FIG. 94 (SEQ ID NO:259), FIG. 96 (SEQ ID NO:261), FIG. 98 (SEQ ID NO:263), FIG. 100 (SEQ ID NO:285), FIG. 102 (SEQ ID NO:290), FIG. 104 (SEQ ID NO:292), FIG. 106 (SEQ ID NO:294), FIG. 108 (SEQ ID NO:310), FIG. 110 (SEQ ID NO:315), FIG. 112 (SEQ ID NO:320), FIG. 114 (SEQ ID NO:325), FIG. 116 (SEQ ID NO:332), FIG. 118 (SEQ ID NO:339), FIG. 120 (SEQ ID NO:341), FIG. 122 (SEQ ID NO:377) or FIG. 124 (SEQ ID NO:423), with its associated signal peptide; or
(c) an extracellular domain of the polypeptide shown in FIG. 2 (SEQ ID NO:2), FIG. 4 (SEQ ID NO:4), FIG. 6 (SEQ ID NO:212), FIG. 9 (SEQ ID NO:218), FIG. 91 (SEQ ID NO:23), FIG. 13 (SEQ ID NO:28), FIG. 15 (SEQ ID NO:34), FIG. 17 (SEQ ID NO:39), FIG. 19 (SEQ ID NO:49), FIG. 22 (SEQ ID NO:59), FIG. 24 (SEQ ID NO:64), FIG. 26 (SEQ ID NO:69), FIG. 28 (SEQ ID NO:71), FIG. (SEQ ID NO:73), FIG. 32 (SEQ ID NO:84), FIG. 34 (SEQ ID NO:91), FIG. 36 (SEQ ID NO:96), FIG. 38 (SEQ ID NO:104), FIG. 40 (SEQ ID NO:109), FIG. 42 (SEQ ID NO:114), FIG. 44 (SEQ ID NO:119), FIG. 46 (SEQ ID NO:127), FIG. 48 (SEQ ID NO:132), FIG. 50 (SEQ ID NO:137), FIG. 52 (SEQ ID NO:142), FIG. 54 (SEQ ID NO:148), FIG. 56 (SEQ ID NO:153), FIG. 58 (SEQ ID NO:159), FIG. 60 (SEQ ID NO:164), FIG. 62 (SEQ ID NO:170), FIG. 64 (SEQ ID NO:175), FIG. 66 (SEQ ID NO:177), FIG. 68 (SEQ ID NO:185), FIG. 70 (SEQ ID NO:190), FIG. 72 (SEQ ID NO:195), FIG. 74 (SEQ ID NO:201), FIG. 76 (SEQ ID NO:207), FIG. 78 (SEQ ID NO:213), FIG. 80 (SEQ ID NO:221), FIG. 82 (SEQ ID NO:227), FIG. 84 (SEQ ID NO:236), FIG. 86 (SEQ ID NO:245), FIG. 88 (SEQ ID NO:250), FIG. 90 (SEQ ID NO:255), FIG. 92 (SEQ ID NO:257), FIG. 94 (SEQ ID NO:259), FIG. 96 (SEQ ID NO:261), FIG. 98 (SEQ ID NO:263), FIG. 100 (SEQ ID NO:285), FIG. 102 (SEQ ID NO:290), FIG. 104 (SEQ ID NO:292), FIG. 106 (SEQ ID NO:294), FIG. 108 (SEQ ID NO:310), FIG. 110 (SEQ ID NO:315), FIG. 112 (SEQ ID NO:320), FIG. 114 (SEQ ID NO:325), FIG. 116 (SEQ ID NO:332), FIG. 118 (SEQ ID NO:339), FIG. 120 (SEQ ID NO:341), FIG. 122 (SEQ ID NO:377) or FIG. 124 (SEQ ID NO:423), lacking its associated signal peptide.
21. A method of detecting a PRO245 polypeptide in a sample suspected of containing a PRO245 polypeptide, said method comprising contacting said sample with a PRO1868 polypeptide and determining the formation of a PRO245/PRO1868 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO245 polypeptide in said sample.
22. The method according toclaim 21, wherein said sample comprises cells suspected of expressing said PRO245 polypeptide.
23. The method according toclaim 21, wherein said PRO1868 polypeptide is labeled with a detectable label.
24. The method according toclaim 21, wherein said PRO1868 polypeptide is attached to a solid support.
25. A method of detecting a PRO1868 polypeptide in a sample suspected of containing a PRO1868 polypeptide, said method comprising contacting said sample with a PRO245 polypeptide and determining the formation of a PRO245/PRO1868 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO1868 polypeptide in said sample.
26. The method according toclaim 25, wherein said sample comprises cells suspected of expressing said PRO1868 polypeptide.
27. The method according toclaim 25, wherein said PRO245 polypeptide is labeled with a detectable label.
28. The method according toclaim 25, wherein said PRO245 polypeptide is attached to a solid support.
29. A method of linking a bioactive molecule to a cell expressing a PRO245 polypeptide, said method comprising contacting said cell with a PRO1868 polypeptide that is bound to said bioactive molecule and allowing said PRO245 and PRO1868 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.
30. The method according toclaim 29, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.
31. The method according toclaim 29, wherein said bioactive molecule causes the death of said cell.
32. A method of linking a bioactive molecule to a cell expressing a PRO1868 polypeptide, said method comprising contacting said cell with a PRO245 polypeptide that is bound to said bioactive molecule and allowing said PRO245 and PRO1868 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.
33. The method according toclaim 32, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.
34. The method according toclaim 32, wherein said bioactive molecule causes the death of said cell.
35. A method of modulating at least one biological activity of a cell expressing a PRO245 polypeptide, said method comprising contacting said cell with a PRO1868 polypeptide or an anti-PRO245 antibody, whereby said PRO1868 polypeptide or said anti-PRO245 antibody binds to said PRO245 polypeptide, thereby modulating at least one biological activity of said cell.
36. The method according toclaim 35, wherein said cell is killed.
37. A method of modulating at least one biological activity of a cell expressing a PRO1868 polypeptide, said method comprising contacting said cell with a PRO245 polypeptide or an anti-PRO1868 antibody, whereby said PRO245 polypeptide or said anti-PRO1868 antibody binds to said PRO1868 polypeptide, thereby modulating at least one biological activity of said cell.
38. The method according toclaim 37, wherein said cell is killed.
US09/904,8381997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the sameAbandonedUS20030148370A1 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
US09/904,838US20030148370A1 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same

Applications Claiming Priority (121)

Application NumberPriority DateFiling DateTitle
US5911997P1997-09-171997-09-17
US5911597P1997-09-171997-09-17
US5912297P1997-09-171997-09-17
US5918497P1997-09-171997-09-17
US5911397P1997-09-171997-09-17
US5912197P1997-09-171997-09-17
US5911797P1997-09-171997-09-17
US5926697P1997-09-181997-09-18
US5926397P1997-09-181997-09-18
US6212597P1997-10-151997-10-15
US6228597P1997-10-171997-10-17
US6228797P1997-10-171997-10-17
US6348697P1997-10-211997-10-21
US6304597P1997-10-241997-10-24
US6312797P1997-10-241997-10-24
US6312197P1997-10-241997-10-24
US6312897P1997-10-241997-10-24
US6281497P1997-10-241997-10-24
US6281697P1997-10-241997-10-24
US6312097P1997-10-241997-10-24
US6332997P1997-10-271997-10-27
US6332797P1997-10-271997-10-27
US6356497P1997-10-281997-10-28
US6354197P1997-10-281997-10-28
US6354497P1997-10-281997-10-28
US6354297P1997-10-281997-10-28
US6354997P1997-10-281997-10-28
US6355097P1997-10-281997-10-28
US6421597P1997-10-291997-10-29
US6373897P1997-10-291997-10-29
US6373597P1997-10-291997-10-29
US6343597P1997-10-291997-10-29
US6373297P1997-10-291997-10-29
US6373497P1997-10-291997-10-29
US6370497P1997-10-291997-10-29
US6410397P1997-10-311997-10-31
US6387097P1997-10-311997-10-31
US6424897P1997-11-031997-11-03
US6480997P1997-11-071997-11-07
US6518697P1997-11-121997-11-12
US6584697P1997-11-171997-11-17
US6569397P1997-11-181997-11-18
US6636497P1997-11-211997-11-21
US6612097P1997-11-211997-11-21
US6651197P1997-11-241997-11-24
US6677297P1997-11-241997-11-24
US6646697P1997-11-241997-11-24
US6677097P1997-11-241997-11-24
US6645397P1997-11-241997-11-24
US6684097P1997-11-251997-11-25
US6942597P1997-12-121997-12-12
US8802698P1998-06-041998-06-04
US9980398P1998-09-101998-09-10
PCT/US1998/018824WO1999014327A2 (en)1997-09-171998-09-10Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
WOPCT/US98/188241998-09-10
US10026298P1998-09-141998-09-14
WOPCT/US98/191771998-09-14
PCT/US1998/019177WO1999014234A2 (en)1997-09-171998-09-14Promotion or inhibition of angiogenesis and cardiovascularization
WOPCT/US98/193301998-09-16
PCT/US1998/019330WO1999014328A2 (en)1997-09-171998-09-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10085898P1998-09-171998-09-17
WOPCT/US98/194371998-09-17
PCT/US1998/019437WO1999014241A2 (en)1997-09-171998-09-17Compositions and methods for the treatment of immune related diseases
US10408098P1998-10-131998-10-13
US10930498P1998-11-201998-11-20
PCT/US1998/025108WO1999028462A2 (en)1997-12-031998-12-01Polypeptides and nucleic acids encoding the same
WOPCT/US98/251081998-12-01
US11329698P1998-12-221998-12-22
US14304899P1999-07-071999-07-07
US14569899P1999-07-261999-07-26
US14622299P1999-07-281999-07-28
WOPCT/US99/205941999-09-08
PCT/US1999/020594WO2000015666A2 (en)1998-09-101999-09-08Compositions and methods for the treatment of tumors
PCT/US1999/020944WO2000015792A2 (en)1998-09-141999-09-13Promotion or inhibition of angiogenesis and cardiovascularization
WOPCT/US99/209441999-09-13
WOPCT/US99/210901999-09-15
PCT/US1999/021547WO2000015797A2 (en)1998-09-171999-09-15Compositions and methods for the treatment of immune related diseases
WOPCT/US99/215471999-09-15
PCT/US1999/021090WO2000015796A2 (en)1998-09-161999-09-15Secreted and transmembrane polypeptides and nucleic acids encoding the same
WOPCT/US99/230891999-10-05
PCT/US1999/023089WO2000021996A2 (en)1998-10-131999-10-05Methods and compositions for inhibiting neoplastic cell growth
WOPCT/US99/282141999-11-29
PCT/US1999/028214WO2001019987A1 (en)1999-09-131999-11-29Promotion or inhibition of angiogenesis and cardiovascularization
WOPCT/US99/283131999-11-30
PCT/US1999/028313WO2000032221A2 (en)1998-12-011999-11-30Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US1999/028301WO2000032776A2 (en)1998-12-011999-12-01Secreted amd transmembrane polypeptides and nucleic acids encoding the same
WOPCT/US99/283011999-12-01
WOPCT/US99/285651999-12-02
PCT/US1999/028564WO2000055319A1 (en)1999-03-121999-12-02Methods and compositions for inhibiting neoplastic cell growth
PCT/US1999/028565WO2000037638A2 (en)1998-12-221999-12-02Methods and compositions for inhibiting neoplastic cell growth
WOPCT/US99/285641999-12-02
PCT/US1999/030095WO2000037640A2 (en)1998-12-221999-12-16Compositions and methods for the treatment of tumor
WOPCT/US99/300951999-12-16
WOPCT/US99/309111999-12-20
PCT/US1999/030999WO2001005836A1 (en)1999-07-201999-12-20Polypeptidic compositions and methods for the treatment of tumors
WOPCT/US99/309991999-12-20
PCT/US1999/030911WO2000075316A1 (en)1999-06-021999-12-20Methods and compositions for inhibiting neoplastic cell growth
WOPCT/US00/002192000-01-05
PCT/US2000/000219WO2000053753A2 (en)1999-03-082000-01-05Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US2000/003565WO2001053486A1 (en)1999-03-082000-02-11Compositions and methods for the treatment of tumor
WOPCT/US00/035652000-02-11
WOPCT/US00/044142000-02-22
PCT/US2000/004414WO2001004311A1 (en)1999-07-072000-02-22Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/005004WO2000053757A2 (en)1999-03-082000-02-24Promotion or inhibition of angiogenesis and cardiovascularization
WOPCT/US00/050042000-02-24
WOPCT/US00/058412000-03-02
PCT/US2000/005841WO2000053758A2 (en)1999-03-082000-03-02Compositions and methods for the treatment of immune related diseases
PCT/US2000/007377WO2001019991A1 (en)1999-09-152000-03-20Compositions and methods for the treatment of immune related diseases
WOPCT/US00/073772000-03-20
PCT/US2000/008439WO2000073454A1 (en)1999-06-022000-03-30Secreted and transmembrane polypeptides and nucleic acids encoding the same
WOPCT/US00/084392000-03-30
PCT/US2000/014042WO2000077037A2 (en)1999-06-152000-05-22Secreted and transmembrane polypeptides and nucleic acids encoding the same
WOPCT/US00/140422000-05-22
WOPCT/US00/152642000-06-02
PCT/US2000/015264WO2000073452A2 (en)1999-06-022000-06-02Compositions and methods for the treatment of immune related diseases
PCT/US2000/020710WO2001009327A2 (en)1999-07-282000-07-28Method of preventing the injury or death of retinal cells and treating ocular diseases
WOPCT/US00/207102000-07-28
PCT/US2000/023328WO2001016318A2 (en)1999-09-012000-08-24Secreted and transmembrane polypeptides and nucleic acids encoding the same
WOPCT/US00/233282000-08-24
US66535000A2000-09-182000-09-18
US09/904,838US20030148370A1 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
US66535000AContinuation1994-09-082000-09-18

Publications (1)

Publication NumberPublication Date
US20030148370A1true US20030148370A1 (en)2003-08-07

Family

ID=43706158

Family Applications (58)

Application NumberTitlePriority DateFiling Date
US09/902,736GrantedUS20030049676A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,615AbandonedUS20030092002A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,903AbandonedUS20030044839A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,759AbandonedUS20030077654A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,692AbandonedUS20030054400A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,572AbandonedUS20030108983A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,634AbandonedUS20030082540A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,713AbandonedUS20030082541A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,749Expired - Fee RelatedUS7147853B2 (en)1997-09-172001-07-11Anti-pro211 polypeptide antibodies
US09/903,823AbandonedUS20030104381A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,806AbandonedUS20030130489A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,786AbandonedUS20030044793A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,640Expired - Fee RelatedUS7208308B2 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,603GrantedUS20030148419A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,520AbandonedUS20030054401A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,925AbandonedUS20030096233A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,119AbandonedUS20030049621A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids enconding the same
US09/903,562Expired - LifetimeUS6965015B2 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,125Expired - LifetimeUS6664376B2 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,786Expired - Fee RelatedUS7557192B2 (en)1997-09-172001-07-12Anti-PRO335 antibodies
US09/904,766AbandonedUS20030152999A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,859AbandonedUS20030036060A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,056AbandonedUS20030054441A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,877AbandonedUS20030186358A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,088AbandonedUS20030073077A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,992AbandonedUS20030135025A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,938AbandonedUS20030211569A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,381Expired - LifetimeUS6818746B2 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,348AbandonedUS20030064923A1 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,838AbandonedUS20030148370A1 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,532Expired - Fee RelatedUS7151160B2 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,553AbandonedUS20030059828A1 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,449Expired - LifetimeUS6965011B2 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,462Expired - LifetimeUS6878807B2 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,485AbandonedUS20030064367A1 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,820AbandonedUS20030036094A1 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,956AbandonedUS20030049622A1 (en)1995-12-012001-07-14Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,722Expired - LifetimeUS6946262B2 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,618Expired - LifetimeUS6828146B2 (en)1997-09-172001-07-16Nucleic acid encoding PRO229 polypeptides
US09/906,777AbandonedUS20030148371A1 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,742AbandonedUS20030023054A1 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,646Expired - LifetimeUS6852848B2 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,838Expired - Fee RelatedUS7070979B2 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,760AbandonedUS20030096340A1 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,700Expired - LifetimeUS6723535B2 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,815Expired - Fee RelatedUS7094567B2 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,925AbandonedUS20030054352A1 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,942Expired - Fee RelatedUS7087738B2 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,728AbandonedUS20030190611A1 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,613AbandonedUS20030027145A1 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,575AbandonedUS20030073079A1 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/908,093AbandonedUS20030017498A1 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,794Expired - LifetimeUS6635468B2 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,979AbandonedUS20030082542A1 (en)1994-09-082001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,652AbandonedUS20030104469A1 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/909,064Expired - LifetimeUS6818449B2 (en)1997-09-172001-07-18Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/908,576AbandonedUS20040005553A1 (en)1997-09-172001-07-18Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/909,204AbandonedUS20030036061A1 (en)1997-09-172001-07-18Secreted and transmembrane polypeptides and nucleic acids encoding the same

Family Applications Before (29)

Application NumberTitlePriority DateFiling Date
US09/902,736GrantedUS20030049676A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,615AbandonedUS20030092002A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,903AbandonedUS20030044839A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,759AbandonedUS20030077654A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,692AbandonedUS20030054400A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,572AbandonedUS20030108983A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,634AbandonedUS20030082540A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,713AbandonedUS20030082541A1 (en)1997-09-172001-07-10Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,749Expired - Fee RelatedUS7147853B2 (en)1997-09-172001-07-11Anti-pro211 polypeptide antibodies
US09/903,823AbandonedUS20030104381A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,806AbandonedUS20030130489A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,786AbandonedUS20030044793A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,640Expired - Fee RelatedUS7208308B2 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,603GrantedUS20030148419A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,520AbandonedUS20030054401A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,925AbandonedUS20030096233A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,119AbandonedUS20030049621A1 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids enconding the same
US09/903,562Expired - LifetimeUS6965015B2 (en)1997-09-172001-07-11Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,125Expired - LifetimeUS6664376B2 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,786Expired - Fee RelatedUS7557192B2 (en)1997-09-172001-07-12Anti-PRO335 antibodies
US09/904,766AbandonedUS20030152999A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,859AbandonedUS20030036060A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,056AbandonedUS20030054441A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,877AbandonedUS20030186358A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,088AbandonedUS20030073077A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,992AbandonedUS20030135025A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,938AbandonedUS20030211569A1 (en)1997-09-172001-07-12Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,381Expired - LifetimeUS6818746B2 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,348AbandonedUS20030064923A1 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same

Family Applications After (28)

Application NumberTitlePriority DateFiling Date
US09/904,532Expired - Fee RelatedUS7151160B2 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,553AbandonedUS20030059828A1 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,449Expired - LifetimeUS6965011B2 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,462Expired - LifetimeUS6878807B2 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,485AbandonedUS20030064367A1 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,820AbandonedUS20030036094A1 (en)1997-09-172001-07-13Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,956AbandonedUS20030049622A1 (en)1995-12-012001-07-14Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,722Expired - LifetimeUS6946262B2 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,618Expired - LifetimeUS6828146B2 (en)1997-09-172001-07-16Nucleic acid encoding PRO229 polypeptides
US09/906,777AbandonedUS20030148371A1 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,742AbandonedUS20030023054A1 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,646Expired - LifetimeUS6852848B2 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,838Expired - Fee RelatedUS7070979B2 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,760AbandonedUS20030096340A1 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,700Expired - LifetimeUS6723535B2 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,815Expired - Fee RelatedUS7094567B2 (en)1997-09-172001-07-16Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,925AbandonedUS20030054352A1 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,942Expired - Fee RelatedUS7087738B2 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,728AbandonedUS20030190611A1 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,613AbandonedUS20030027145A1 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,575AbandonedUS20030073079A1 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/908,093AbandonedUS20030017498A1 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,794Expired - LifetimeUS6635468B2 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,979AbandonedUS20030082542A1 (en)1994-09-082001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,652AbandonedUS20030104469A1 (en)1997-09-172001-07-17Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/909,064Expired - LifetimeUS6818449B2 (en)1997-09-172001-07-18Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/908,576AbandonedUS20040005553A1 (en)1997-09-172001-07-18Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/909,204AbandonedUS20030036061A1 (en)1997-09-172001-07-18Secreted and transmembrane polypeptides and nucleic acids encoding the same

Country Status (1)

CountryLink
US (58)US20030049676A1 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20040254101A1 (en)*1995-06-062004-12-16Human Genome Sciences, Inc.Colon specific gene and protein and cancer
US20030083461A1 (en)*1997-06-162003-05-01Genentech, Inc.Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE447583T1 (en)*1997-09-172009-11-15Genentech Inc POLYPEPTIDES AND NUCLEIC ACIDS CODING THEREFOR
EP1205546B1 (en)*1997-10-242005-11-23Genentech, Inc.Polypeptide and nucleic acids encoding the same
US20030039648A1 (en)*1998-09-162003-02-27Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumor
US7273726B2 (en)1997-11-212007-09-25Genentech, Inc.Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US5942606A (en)*1997-11-241999-08-24Incyte Pharmaceuticals, Inc.Viral receptor protein
US6432690B1 (en)*1998-01-162002-08-13Incyte Genomics, Inc.Human aspartic proteases
US7339033B2 (en)*1998-06-262008-03-04Genentech, Inc.Pro1481
US20050053983A1 (en)*1998-11-202005-03-10Fuso Pharmaceutical Industries, Ltd.Novel serine protease BSSP4
US7026449B2 (en)*1999-01-052006-04-11Genentech, Inc.Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2361905T3 (en)*1999-03-112011-06-24Merck Serono Sa VASCULAR ADHESION MOLECULES AND MODULATION OF THEIR FUNCTION.
US7514408B1 (en)1999-12-022009-04-07Elan Pharmaceuticals, Inc.β-secretase enzyme compositions and methods
US7122631B2 (en)*2000-02-222006-10-17Genentech, Inc.Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040197784A1 (en)*2001-02-222004-10-07Miano Joseph MichaelRetinoid inducible proteins of vascular smooth muscle cells and uses thereof
US7223558B2 (en)*2001-07-112007-05-29Bristol-Myers Squibb CompanyPolynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
MXPA04010091A (en)*2002-04-172004-12-13Genentech IncCompositions and methods for the diagnosis and treatment of tumor.
US7273754B2 (en)*2002-09-132007-09-25The Board Of Regents Of The University Of OklahomaCore 1 β3-galactosyltransferase specific molecular chaperones, nucleic acids, and methods of use thereof
EP1590441A4 (en)*2003-02-052006-11-02Millennium Pharm IncScreening for compounds for hematological disorders treatment
ES2384622T3 (en)*2003-05-302012-07-10Agensys, Inc. Variants of the prostate stem cell antigen (PSCA) and their sub-sequences
US7595379B2 (en)*2003-05-302009-09-29Agensys, Inc.Antibodies and related molecules that bind to PSCA proteins
US7541442B2 (en)*2003-05-302009-06-02Agensys, Inc.Antibodies and related molecules that bind to PSCA proteins
EP1666501A4 (en)*2003-08-112008-12-24Chugai Pharmaceutical Co LtdSugar chain-modified anti-hm1.24 antibody
US20050108643A1 (en)*2003-11-172005-05-19Nokia CorporationTopographic presentation of media files in a media diary application
WO2005093607A1 (en)*2004-02-272005-10-06Ebay Inc.Method and system to monitor a diverse heterogeneous application environment
US8983966B2 (en)2004-02-272015-03-17Ebay Inc.Method and system to monitor a diverse heterogeneous application environment
US8697139B2 (en)2004-09-212014-04-15Frank M. PhillipsMethod of intervertebral disc treatment using articular chondrocyte cells
EP2275547B1 (en)2004-12-132014-03-05Alethia Biotherapeutics Inc.Polynucleotides and polypeptide sequences involved in the process of bone remodeling
RU2007137489A (en)2005-03-102009-04-20Дженентек, Инк. (Us) METHODS AND COMPOSITIONS FOR MODULATION OF VESSEL INTEGRITY
DE102005041780A1 (en)*2005-09-012007-03-08Leica Microsystems Nussloch Gmbh Device for the production of tissue arrays
US7772604B2 (en)2006-01-052010-08-10IllumitexSeparate optical device for directing light from an LED
EP2010226B1 (en)*2006-04-072014-01-15The Research Foundation of State University of New YorkTranscobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9044461B2 (en)2006-04-072015-06-02The Research Foundation Of State University Of New YorkTranscobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US8106004B2 (en)*2006-07-282012-01-31Children's Memorial HospitalMethods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US20100105610A1 (en)*2006-07-282010-04-29Children's Memorial HospitalMethods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells
US8007797B2 (en)*2006-09-282011-08-30Merck Serono S.A.Junctional adhesion molecule-C (JAM-C) binding compounds and methods of their use
WO2008042351A2 (en)2006-10-022008-04-10Illumitex, Inc.Led system and method
CN101965363A (en)*2006-11-022011-02-02丹尼尔·J·卡鹏 Hybrid immunoglobulin with active part
GB2444998A (en)2006-12-112008-06-25Nec CorpDedicated radio resource control
PT2190469E (en)*2007-09-042015-06-25Compugen LtdPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
JP2011512037A (en)2008-02-082011-04-14イルミテックス， インコーポレイテッド System and method for emitter layer shaping
CA2733445C (en)*2008-08-122013-03-19Wyeth LlcPyrrolo[4,3,2-de]quinolin-8-amine compounds and methods of their preparation and use
TW201034256A (en)2008-12-112010-09-16Illumitex IncSystems and methods for packaging light-emitting diode devices
US20100331244A1 (en)*2009-06-012010-12-30The University Of TokyoPharmaceutical composition, food or drink, and methods related thereto
US8585253B2 (en)2009-08-202013-11-19Illumitex, Inc.System and method for color mixing lens array
US8449128B2 (en)2009-08-202013-05-28Illumitex, Inc.System and method for a lens and phosphor layer
WO2011027132A1 (en)2009-09-032011-03-10Cancer Research Technology LimitedClec14a inhibitors
CN102791739B (en)2009-10-192014-10-15霍夫曼-拉罗奇有限公司Modulators of hepatocyte growth factor activator
US8697386B2 (en)2009-10-222014-04-15Genentech, Inc.Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
US8116923B2 (en)*2009-11-192012-02-14Honeywell InternationalStabilized approach monitor
WO2012135500A1 (en)2011-03-292012-10-04The General Hospital CorporationEngineered thioredoxin-like fold proteins
AU2012279237B2 (en)2011-07-012016-09-29Ngm Biopharmaceuticals, Inc.Compositions, uses and methods for treatment of metabolic disorders and diseases
US9120858B2 (en)2011-07-222015-09-01The Research Foundation Of State University Of New YorkAntibodies to the B12-transcobalamin receptor
NZ630484A (en)2012-11-282017-04-28Ngm Biopharmaceuticals IncCompositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en)2012-11-282016-03-22Ngm Biopharmaceuticals, Inc.Compositions comprising variants and fusions of FGF19 polypeptides
KR102724421B1 (en)2012-12-272024-10-30엔지엠 바이오파마슈티컬스, 아이엔씨.Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en)2012-12-272016-03-01Ngm Biopharmaceuticals, Inc.Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US11220556B2 (en)2013-03-152022-01-11Biomolecular Holdings LlcHybrid immunoglobulin containing non-peptidyl linkage
CN105828878A (en)2013-10-282016-08-03恩格姆生物制药公司 Cancer Models and Related Methods
EP3097122B9 (en)2014-01-242020-11-11NGM Biopharmaceuticals, Inc.Antibodies binding beta klotho domain 2 and methods of use thereof
KR102587838B1 (en)2014-03-142023-10-12바이오몰레큘러 홀딩스 엘엘씨Hybrid immunoglobulin containing non-peptidyl linkage
WO2015183890A2 (en)2014-05-282015-12-03Ngm Biopharmaceuticals, Inc.Methods and compositions for the treatment of metabolic disorders and diseases
EP3155005A4 (en)2014-06-162018-07-11NGM Biopharmaceuticals, Inc.Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9616114B1 (en)2014-09-182017-04-11David Gordon BermudesModified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
RU2729161C2 (en)2014-10-232020-08-04ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК.Pharmaceutical compositions containing peptide versions, and methods of using them
US10434144B2 (en)2014-11-072019-10-08Ngm Biopharmaceuticals, Inc.Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10676723B2 (en)2015-05-112020-06-09David Gordon BermudesChimeric protein toxins for expression by therapeutic bacteria
US10800843B2 (en)2015-07-292020-10-13Ngm Biopharmaceuticals, Inc.Beta klotho-binding proteins
EP3888672A1 (en)2015-11-092021-10-06NGM Biopharmaceuticals, Inc.Methods for treatment of bile acid-related disorders
US10753936B2 (en)2016-07-222020-08-25Van Andel Research InstituteMethod of detecting the level of a glycan
EP3503882A4 (en)2016-08-262020-07-29NGM Biopharmaceuticals, Inc.Methods of treating fibroblast growth factor 19-mediated cancers and tumors
US11180535B1 (en)2016-12-072021-11-23David Gordon BermudesSaccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en)2016-12-072021-09-28David Gordon BermudesChimeric protein toxins for expression by therapeutic bacteria
US20190388548A1 (en)*2018-06-262019-12-26Tzu Chi UniversityMethod for providing ocular neuroprotection or for preventing, treating or alleviating the effects of, an ocular disease associated with retinal ganglion cell death
JP2023519304A (en)*2020-03-272023-05-10ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー Immunotherapy targets in multiple myeloma and methods for their identification
KR102784657B1 (en)*2022-04-082025-03-21전남대학교산학협력단A Pharmaceutical composition for treating neuropathic pain comprising Mincle inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6027917A (en)*1997-12-102000-02-22Genetics Institute, Inc.Bone morphogenetic protein (BMP)-17 and BMP-18 compositions
US20030069408A1 (en)*1997-08-212003-04-10Human Genome Sciences, Inc.Human nodal and lefty homologues

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4456550A (en)*1982-11-221984-06-26President And Fellows Of Harvard CollegeVascular permeability factor
US5036003A (en)*1987-08-211991-07-30Monsanto CompanyAntibodies to VPF
US5008196A (en)*1987-08-211991-04-16Monsanto CompanyStimulation of endothelial cell growth
US4950647A (en)*1988-10-041990-08-21Nucleic Acid Research InstituteT cell immunopotentiator
US5240848A (en)*1988-11-211993-08-31Monsanto CompanyDna sequences encoding human vascular permeability factor having 189 amino acids
US5194596A (en)*1989-07-271993-03-16California Biotechnology Inc.Production of vascular endothelial cell growth factor
US5840496A (en)*1990-10-091998-11-24Chiron CorporationMethod for diagnosing endometrial cancer
US6407213B1 (en)*1991-06-142002-06-18Genentech, Inc.Method for making humanized antibodies
US5408040A (en)*1991-08-301995-04-18University Of South FloridaConnective tissue growth factor(CTGF)
US5817310A (en)*1991-12-021998-10-06Cor Therapeutics, Inc.Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5635177A (en)1992-01-221997-06-03Genentech, Inc.Protein tyrosine kinase agonist antibodies
US5958403A (en)*1992-02-281999-09-28Beth Israel Hospital AssociationMethods and compounds for prevention of graft rejection
GB9214857D0 (en)*1992-07-131992-08-26Medical Res CouncilHuman nucleic acid fragments and their use
US5561053A (en)1994-08-051996-10-01Genentech, Inc.Method for selecting high-expressing host cells
US5648376A (en)*1995-01-191997-07-15Pharmagenesis, Inc.Immunosuppressant diterpene compound
US5707829A (en)1995-08-111998-01-13Genetics Institute, Inc.DNA sequences and secreted proteins encoded thereby
US5916758A (en)*1995-09-081999-06-29Hurle; Mark RobertSmooth muscle cell-derived migration factor
US6613544B1 (en)*1995-12-222003-09-02Amgen Inc.Osteoprotegerin
US5831056A (en)*1996-06-071998-11-03Genetics Institute, Inc.Secreted proteins and polynucleotides encoding them
US5916751A (en)*1996-08-271999-06-29University Of South FloridaMethod for the diagnosis of selected adenocarcinomas
US5824504A (en)1996-09-261998-10-20Elshourbagy; Nabil A.Human 7-transmembrane receptor and DNA
US5891637A (en)1996-10-151999-04-06Genentech, Inc.Construction of full length cDNA libraries
WO1998021328A2 (en)*1996-11-131998-05-22Sagami Chemical Research CenterHuman proteins having transmembrane domains and dnas encoding these proteins
US6046314A (en)*1997-03-062000-04-04Bristol-Myers Squibb Co.Spα: a novel scavenger receptor cysteine-rich domain-containing polypeptide, and monoclonal antibodies thereto
WO1999058660A1 (en)*1998-05-121999-11-18Human Genome Sciences, Inc.97 human secreted proteins
WO1998039446A2 (en)1997-03-071998-09-11Human Genome Sciences, Inc.70 human secreted proteins
US6258939B1 (en)*1997-03-102001-07-10The Regents Of The University Of CaliforniaPSCA antibodies and hybridomas producing them
US5801193A (en)*1997-04-151998-09-01Immune Modulation, Inc.Compositions and methods for immunosuppressing
US5981263A (en)*1997-07-211999-11-09Incyte Pharmaceuticals, Inc.Human matrilin-3
US6302685B1 (en)*1997-09-162001-10-16University Of Medicine And Dentistry Of New JerseyHuman lysosomal protein and methods of its use
ATE447583T1 (en)1997-09-172009-11-15Genentech Inc POLYPEPTIDES AND NUCLEIC ACIDS CODING THEREFOR
AU9312198A (en)1997-09-171999-04-05Genentech Inc.Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
AU9395998A (en)1997-09-171999-04-05Genentech Inc.Compositions and methods for the treatment of immune related diseases
US6030831A (en)*1997-09-192000-02-29Genetech, Inc.Tie ligand homologues
US5942606A (en)*1997-11-241999-08-24Incyte Pharmaceuticals, Inc.Viral receptor protein
US6232454B1 (en)*1998-02-272001-05-15Incyte Genomics, Inc.Human proteinase molecules
CA2322711A1 (en)1998-02-271999-09-02Sagami Chemical Research CenterHuman proteins having transmembrane domains and dnas encoding these proteins
CA2340616A1 (en)*1998-08-242000-03-02Alphagene, Inc.Secreted proteins and polynucleotides encoding them
KR20010103576A (en)1998-09-102001-11-23제넨테크, 인크.Compositions and Methods for The Treatment of Tumor
US6406884B1 (en)*1999-06-182002-06-18Millennium Pharmaceuticals, Inc.Secreted proteins and uses thereof
US20030027998A1 (en)*1998-10-302003-02-06Holtzman Douglas A.Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
EP1067182A3 (en)*1999-07-082001-11-21Helix Research InstituteSecretory protein or membrane protein
AU7452300A (en)*1999-10-012001-05-10Kyowa Hakko Kogyo Co. Ltd.Shear stress-response dna
AU2404001A (en)*2000-01-062001-07-16Protegene Inc.Human proteins having hydrophobic domains and dnas encoding these proteins
US6436703B1 (en)*2000-03-312002-08-20Hyseq, Inc.Nucleic acids and polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20030069408A1 (en)*1997-08-212003-04-10Human Genome Sciences, Inc.Human nodal and lefty homologues
US6027917A (en)*1997-12-102000-02-22Genetics Institute, Inc.Bone morphogenetic protein (BMP)-17 and BMP-18 compositions

Also Published As

Publication numberPublication date
US20030082541A1 (en)2003-05-01
US20030152922A1 (en)2003-08-14
US7147853B2 (en)2006-12-12
US20030039972A1 (en)2003-02-27
US20030186358A1 (en)2003-10-02
US20030073077A1 (en)2003-04-17
US20030036061A1 (en)2003-02-20
US20030148371A1 (en)2003-08-07
US20030017463A1 (en)2003-01-23
US20030027146A1 (en)2003-02-06
US20030039971A1 (en)2003-02-27
US7094567B2 (en)2006-08-22
US20030108983A1 (en)2003-06-12
US20030049621A1 (en)2003-03-13
US6965015B2 (en)2005-11-15
US20030073079A1 (en)2003-04-17
US20030104381A1 (en)2003-06-05
US20030044839A1 (en)2003-03-06
US20030054352A1 (en)2003-03-20
US20030017498A1 (en)2003-01-23
US20030059829A1 (en)2003-03-27
US6635468B2 (en)2003-10-21
US20030027145A1 (en)2003-02-06
US20030049676A1 (en)2003-03-13
US7070979B2 (en)2006-07-04
US7557192B2 (en)2009-07-07
US20040005553A1 (en)2004-01-08
US20030104469A1 (en)2003-06-05
US6664376B2 (en)2003-12-16
US20030096233A1 (en)2003-05-22
US20030082542A1 (en)2003-05-01
US6818449B2 (en)2004-11-16
US20030064367A1 (en)2003-04-03
US20030082540A1 (en)2003-05-01
US20030092002A1 (en)2003-05-15
US7208308B2 (en)2007-04-24
US7087738B2 (en)2006-08-08
US20030190610A1 (en)2003-10-09
US20030039969A1 (en)2003-02-27
US20030135025A1 (en)2003-07-17
US20030044793A1 (en)2003-03-06
US20030130489A1 (en)2003-07-10
US6878807B2 (en)2005-04-12
US20030049622A1 (en)2003-03-13
US6852848B2 (en)2005-02-08
US20030113838A1 (en)2003-06-19
US6723535B2 (en)2004-04-20
US20030077654A1 (en)2003-04-24
US7151160B2 (en)2006-12-19
US20030096340A1 (en)2003-05-22
US20030054400A1 (en)2003-03-20
US20030049677A1 (en)2003-03-13
US20030152999A1 (en)2003-08-14
US20030113719A1 (en)2003-06-19
US20030036094A1 (en)2003-02-20
US20030054401A1 (en)2003-03-20
US6828146B2 (en)2004-12-07
US20030064923A1 (en)2003-04-03
US20030027143A1 (en)2003-02-06
US20030036060A1 (en)2003-02-20
US20030059828A1 (en)2003-03-27
US20030190611A1 (en)2003-10-09
US20030211569A1 (en)2003-11-13
US20030045693A1 (en)2003-03-06
US6965011B2 (en)2005-11-15
US20030059772A1 (en)2003-03-27
US20030215904A1 (en)2003-11-20
US6818746B2 (en)2004-11-16
US20030054351A1 (en)2003-03-20
US20030187238A1 (en)2003-10-02
US20030148419A1 (en)2003-08-07
US20030129592A1 (en)2003-07-10
US20030023054A1 (en)2003-01-30
US20030054441A1 (en)2003-03-20
US6946262B2 (en)2005-09-20

Similar Documents

PublicationPublication DateTitle
US6828146B2 (en)Nucleic acid encoding PRO229 polypeptides
US20020192659A1 (en)Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040006211A1 (en)Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030211568A1 (en)Secreted and transmembrane polypeptides and nucleic acids encoding the same

Legal Events

DateCodeTitleDescription
STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION
[8]ページ先頭
©2009-2025 Movatter.jp